Clinical Trials Logo
  1. Home
  2. ARDS
  3. NCT05493839
  4. Details
NCT05493839 Clinical Trial

A Reverification of the Berlin Definition Plateau Criteria in Golmud

Ards Clinical Trial

Official title:
A Reverification of the Berlin Definition Plateau Criteria in Golmud

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT05493839
Other study ID # ARDS in Golmud
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date June 20, 2022
Est. completion date August 30, 2022

Study information
Verified date August 2022
Source Southeast University, China
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is a single-center retrospective study. According to the Berlin diagnostic standard, ARDS patients admitted to the Department of severe Medicine, Golmud People's Hospital from January 2015 to june 2022 were divided into three groups: mild (142mmHg < PaO2/ FiO2 ≤ 213 mmHg), moderate (71mmHg < PaO2/ FiO2 ≤ 142mmHg) and severe (PaO2/ FiO2 ≤ 71 mmHg). The ICU mortality, 28-day mortality, non-ventilator time in ICU, ICU hospitalization time observed respectively.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 160
Est. completion date August 30, 2022
Est. primary completion date August 8, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Meet the diagnostic criteria of ARDS Exclusion Criteria: - length of stay in hospital less than 48h Data missing younger than 18 years or older than 80 years

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
China Zhongda Hospital, Southeast University Nanjing Jiangsu

Sponsors (1)
Lead Sponsor Collaborator
Southeast University, China

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary ICU mortality Mortality during treatment in ICU up to 24 weeks
Primary 28-days mortality rate 28-days mortality rate [ Time Frame: 28 days after discharge ] Mortality at 28 days of hospitalization up to 24 weeks
Secondary Ventilator Free time Ventilator Free time in ICU up to 24 weeks
Secondary Ventilator time Ventilator time in ICU up to 24 weeks
Secondary Hospital length of stay Hospital length of stay in hospital up to 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT04435613 - Clinical and Physiological Assessment of a Nearly Ultra-protective Lung Ventilation Strategy: A Quasi-experimental Preliminary Study in ARDS Patients N/A
Enrolling by invitation NCT05020210 - Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
Completed NCT04468971 - REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia Phase 1
Completed NCT04505592 - Tenecteplase in Patients With COVID-19 Phase 2
Completed NCT04493242 - Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS Phase 2
Withdrawn NCT04909879 - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome Phase 2
Completed NCT02265198 - Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome N/A
Completed NCT01949272 - Optimization of PEEP for Alveolar Recruitment in ARDS N/A
Not yet recruiting NCT01668368 - Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance N/A
Completed NCT01881061 - Lung Sonography in Patients With Acute Respiratory Distress Syndrome in Intensive Care Unit N/A
Completed NCT00808691 - Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit N/A
Completed NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Recruiting NCT04764032 - Right Ventricular Dysfunction in Ventilated Patients With COVID-19
Completed NCT04556513 - Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status
Recruiting NCT06036056 - NMR Based Metabolomics Kinetics in ARDS Patients
Recruiting NCT04503876 - Effects of End-expiratory Positive Pressure Optimization in Intubated Patients With Healthy Lung or Acute Respiratory Distress Syndrome N/A
Recruiting NCT04643691 - Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS Phase 2
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Not yet recruiting NCT05341687 - Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
Recruiting NCT05056090 - Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome. N/A